Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00257140
Other study ID # CR005494
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received November 18, 2005
Last updated June 8, 2011
Start date June 1931
Est. completion date July 1994

Study information

Verified date January 2011
Source Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of levofloxacin, an antibiotic, compared with cefaclor, another antibiotic, in the treatment of adults with chronic bronchitis experiencing rapid onset of worsening of symptoms caused by bacteria.


Description:

This is a randomized, open-label, parallel group, multicenter study to determine the effectiveness and safety of 488 mg of levofloxacin (once daily by mouth for 5 - 7 days) compared with 250 mg of cefaclor (every 8 hours for 7 - 10 days) in adults with chronic bronchitis experiencing rapid onset of worsening of symptoms caused by bacterial infection. The study consists of 3 visits: one visit for screening and enrollment, and 2 visits for assessment of safety and effectiveness (one visit on Days 3 - 5 of the study and one visit [post-therapy] 5 - 7 days after the last dose of the study drug). The total duration of patient participation in the study is approximately 2 weeks. Levofloxacin and cefaclor are antibacterial agents used for the treatment of many types of infections, including infections with a rapid onset and brief duration caused by bacteria. The primary assessment of effectiveness in this study is the microbiologic response to treatment (the rate of elimination of disease-causing bacteria, by patient, and by type of bacteria), 5 - 7 days after the last dose of study drug. Safety evaluations (incidence of adverse events, physical examination, laboratory tests) are performed throughout the study. The study hypothesis is that treatment with levofloxacin is at least as effective and as well tolerated as treatment with cefaclor in adult patients with chronic bronchitis experiencing sudden worsening of symptoms caused by bacterial infection. Levofloxacin 488 mg by mouth once daily for 5 - 7 days, or cefaclor 250 mg by mouth every 8 hours for 7 - 10 days.


Recruitment information / eligibility

Status Completed
Enrollment 367
Est. completion date July 1994
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of chronic bronchitis with a rapid onset of worsening of symptoms caused by bacteria

- history of chronic obstructive lung disease (chronic bronchitis and/or emphysema)

- recent increase in cough

- change in type of sputum (the mucus produced on coughing) and/or an increase in the production of sputum

- received previous antibiotic treatment if the previous treatment lasted for 24 hours or less, or if the previous treatment lasted longer than 24 hours but there was no improvement or stabilization of the disease.

Exclusion Criteria:

- Illness requiring antibiotic treatment by injection into a vein, beneath the skin, or into a muscle, or has a requirement of an antibiotic medication taken orally in addition to the study drug

- infection due to bacteria known (prior to the start of the study) to be resistant to the study drug

- previous allergic or serious adverse reaction to similar antibiotics

- diagnosis of pneumonia, determined by a chest x-ray at the start of the trial

- has cystic fibrosis, seizure disorders, kidney disease, or an unstable psychiatric condition.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
levofloxacin


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. PriCara, Unit of Ortho-McNeil, Inc.

References & Publications (1)

Habib MP, Gentry LO, et al. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis, Infectious Diseases in Clinical Practice 1998;7:101-109

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of elimination of disease-causing bacteria, by patient, and by type of bacteria, 5 - 7 days after the last dose of study drug.
Secondary Clinical response rate (reduction in signs and symptoms) at post-therapy (5 - 7 days after the last dose of study drug). Incidence of adverse events; changes in physical examination and laboratory tests after treatment with the study drug.
See also
  Status Clinical Trial Phase
Completed NCT04016051 - Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections Phase 3
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Recruiting NCT02913365 - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Completed NCT00350987 - Procalcitonin Guided Antibiotic Therapy and Hospitalisation in Patients With Lower Respiratory Tract Infections: The "ProHOSP" Study N/A
Completed NCT00250679 - Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease Phase 3
Completed NCT00371527 - Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease N/A
Completed NCT00042718 - A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis. Phase 3
Completed NCT02902640 - A Non-Interventional Safety Study of Balsamic Bactrim N/A
Completed NCT02879981 - A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis
Recruiting NCT04144699 - Clinical Validation of Omron WheezeScan
Recruiting NCT03320382 - Multiple Breath Washout, a Clinimetric Dataset
Recruiting NCT04415827 - Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases N/A
Completed NCT01354938 - Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis N/A
Completed NCT03535558 - Fluoroquinolone Associated Disability
Recruiting NCT05330637 - Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.
Completed NCT01240174 - Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis N/A
Completed NCT01108185 - Evaluation of the Treatment With Klacid®SR in Patients With Lower Respiratory Tract Infection N/A
Completed NCT00011310 - Cardiopulmonary Effects of Particulate Exposure N/A
Completed NCT00415753 - Procalcitonin as a Marker of Bacterial Pneumonia N/A